ID

21474

Descrizione

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00834665

collegamento

https://clinicaltrials.gov/show/NCT00834665

Keywords

versioni (1)
  1. 23/04/17 23/04/17 -
Caricato su

23 aprile 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Multiple Myeloma NCT00834665

Inglese

Eligibility Multiple Myeloma NCT00834665

1 moduli  
Criteria
Descrizione

Criteria

1. written informed consent must be obtained from all patients before entry into the study
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
2. patients must have a diagnosis of myeloma
Descrizione

Multiple Myeloma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0026764
3. patients must meet one of the following criteria:
Descrizione

Inclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1512693
myeloma has relapsed, progressed, or failed to respond after at least one prior course of therapy.
Descrizione

Relapse or progression

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C0242656
myeloma has responded partially to initial therapy but neither a complete nor a near-complete response has developed after at least 3 cycles or months of initial therapy.
Descrizione

Response to treatment

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0521982
myeloma has high-risk features
Descrizione

Myeloma at high risk

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0332167
UMLS CUI [1,2]
C0026764
4. patients must have measurable disease on study entry.
Descrizione

Measurable disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1513041
5. patients must be between ages 18-80 (inclusive).
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
6. patients should have adequate vital organ function.
Descrizione

Organ function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0678852
7. ecog performance status 0-2
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
8. women of child-bearing potential (wocbp) and their spouses or partners must be willing to use adequate contraception for the duration of the active treatment phase of the study and for at least 4 months after the last dose of chemotherapy. in addition, contraceptive measures must be continued as long as the patient remains on maintenance thalidomide in accordance with the steps program.
Descrizione

Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0700589
key exclusion criteria
Descrizione

Exclusion Criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0680251
subjects who meet any of the following criteria cannot be enrolled in the study:
Descrizione

Exclusion criteria specification

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C2348235
1. pregnant or nursing females
Descrizione

Gynaecological status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. hiv, htlv-1/2 seropositivity
Descrizione

HIV, HTLV

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019682
UMLS CUI [2]
C0086427
3. known history of myelodysplasia
Descrizione

Myelodysplasia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0026985
4. known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).
Descrizione

Chronic active hepatitis or liver cirrhosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0520463
UMLS CUI [2]
C0023890
5. active hepatitis b
Descrizione

Active Hepatitis B

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019163
6. prior autotransplant or allogeneic transplant
Descrizione

Autotransplant or allogeneic transplant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0040736
7. more than 4 distinct, prior courses of therapy for myeloma
Descrizione

Myeloma therapy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0087111
8. history of severe autoimmune disease requiring steroids or other immunosuppressive treatments.
Descrizione

Severe autoimmune disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004364
9. active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis.
Descrizione

connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009782
UMLS CUI [2]
C0042164
UMLS CUI [3]
C0036202
UMLS CUI [4]
C0021390
UMLS CUI [5]
C0026769
10. evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease which might increase the risks of participating in the study
Descrizione

Comorbidity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009488
11. active bacterial, viral or fungal infections.
Descrizione

Infection

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009450
Ritorna all'inizio della pagina

Similar models

Eligibility Multiple Myeloma NCT00834665

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Informed Consent
Item
1. written informed consent must be obtained from all patients before entry into the study
boolean
C0021430 (UMLS CUI [1])
Multiple Myeloma
Item
2. patients must have a diagnosis of myeloma
boolean
C0026764 (UMLS CUI [1])
Inclusion Criteria
Item
3. patients must meet one of the following criteria:
boolean
C1512693 (UMLS CUI [1])
Relapse or progression
Item
myeloma has relapsed, progressed, or failed to respond after at least one prior course of therapy.
boolean
C0277556 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Response to treatment
Item
myeloma has responded partially to initial therapy but neither a complete nor a near-complete response has developed after at least 3 cycles or months of initial therapy.
boolean
C0521982 (UMLS CUI [1])
Myeloma at high risk
Item
myeloma has high-risk features
boolean
C0332167 (UMLS CUI [1,1])
C0026764 (UMLS CUI [1,2])
Measurable disease
Item
4. patients must have measurable disease on study entry.
boolean
C1513041 (UMLS CUI [1])
Age
Item
5. patients must be between ages 18-80 (inclusive).
boolean
C0001779 (UMLS CUI [1])
Organ function
Item
6. patients should have adequate vital organ function.
boolean
C0678852 (UMLS CUI [1])
ECOG performance status
Item
7. ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Contraceptive methods
Item
8. women of child-bearing potential (wocbp) and their spouses or partners must be willing to use adequate contraception for the duration of the active treatment phase of the study and for at least 4 months after the last dose of chemotherapy. in addition, contraceptive measures must be continued as long as the patient remains on maintenance thalidomide in accordance with the steps program.
boolean
C0700589 (UMLS CUI [1])
Exclusion Criteria
Item
key exclusion criteria
boolean
C0680251 (UMLS CUI [1])
Exclusion criteria specification
Item
subjects who meet any of the following criteria cannot be enrolled in the study:
boolean
C0680251 (UMLS CUI [1,1])
C2348235 (UMLS CUI [1,2])
Gynaecological status
Item
1. pregnant or nursing females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV, HTLV
Item
2. hiv, htlv-1/2 seropositivity
boolean
C0019682 (UMLS CUI [1])
C0086427 (UMLS CUI [2])
Myelodysplasia
Item
3. known history of myelodysplasia
boolean
C0026985 (UMLS CUI [1])
Chronic active hepatitis or liver cirrhosis
Item
4. known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy).
boolean
C0520463 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
Active Hepatitis B
Item
5. active hepatitis b
boolean
C0019163 (UMLS CUI [1])
Autotransplant or allogeneic transplant
Item
6. prior autotransplant or allogeneic transplant
boolean
C0040736 (UMLS CUI [1])
Myeloma therapy
Item
7. more than 4 distinct, prior courses of therapy for myeloma
boolean
C0026764 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
Severe autoimmune disease
Item
8. history of severe autoimmune disease requiring steroids or other immunosuppressive treatments.
boolean
C0004364 (UMLS CUI [1])
connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis
Item
9. active immune-mediated diseases including: connective tissue diseases, uveitis, sarcoidosis, inflammatory bowel disease, multiple sclerosis.
boolean
C0009782 (UMLS CUI [1])
C0042164 (UMLS CUI [2])
C0036202 (UMLS CUI [3])
C0021390 (UMLS CUI [4])
C0026769 (UMLS CUI [5])
Comorbidity
Item
10. evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease which might increase the risks of participating in the study
boolean
C0009488 (UMLS CUI [1])
Infection
Item
11. active bacterial, viral or fungal infections.
boolean
C0009450 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial